Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d3fe7dc6459c64519c27abf0d5fe11 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
filingDate |
2005-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2e816ef43f28d7d431a2a2dcd3973b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc3c172ede4ce82c74a315769ee593fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2e9e1044e519fa1d3f3932309bc9db4 |
publicationDate |
2009-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
NZ-548980-A |
titleOfInvention |
Reducing serum proinsulin levels in type 2 diabetics |
abstract |
Provided is the use of an insulin composition including a diketopiperazine in the manufacture of a prandial medicament suitable for administration to a mammalian subject with type 2 diabetes having an elevated proinsulin level, for reducing a risk factor of atherosclerosis in said subject, wherein the medicament is formulated for pulmonary administration, and wherein the medicament is formulated to produce a rapid and early onset of insulin action. |
priorityDate |
2004-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |